Dublin, Oct. 23, 2018 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors: Global Markets" report has been added to ResearchAndMarkets.com's offering.
This report on checkpoint inhibitors provides a detailed analysis of the market based on approved clinical and preclinical developmental candidates that target PD-1/PD-L1, CTLA-4, IDO-1, LAG-3, TIM-3 and CD47/SIRPa. The report analyzes the market trends, key medical needs and provides insights into recent advances in the modulation of checkpoint inhibition in the treatment of cancer through the development of fully human monoclonal antibodies, bispecific antibodies, fusion proteins and Chimeric Antigen Receptor (CAR) T cells.
The immune checkpoint inhibitors are causing a stir amongst oncologist as they have been shown to be effective in the treatment of a variety of cancers, enhancing the immune response to detect and target cancer cells with a lower incidence of side effects compared to conventional chemotherapy and providing durable responses, lasting for many years. Five checkpoint inhibitors have received rapid approval from the U.S. Food and Drug Administration for cancer, including the PD-1 inhibitors Keytruda (pembrolizumab), and Opdivo (nivolumab), the PD-L1 inhibitors Tecentriq (atezoliumab), Bavencio (avelumab) and Imfinzi (durvalumab) and the CTLA-4 inhibitor Yervoy (ipilimumab). In 2011, Bristol Myers Squibb's Yervoy a CTLA-4 inhibitor became one of the first checkpoint inhibitors to be approved in the treatment of metastatic melanoma, despite considerable safety and tolerability concerns. It took a further 3 years before the next checkpoint inhibitor Keytruda, a PD-1 inhibitor was approved for the treatment of advanced unresectable melanoma.
According to clincailtrial.org, there are more than 230 clinical trials underway evaluating checkpoint inhibitors either as a monotherapy or in combination with chemotherapy or targeted therapies these encompass a wide variety of caner sub-types: including 117 Phase 1 trial, 112 Phase 2 trial and 9 Phase 3 studies. Several novel agents are in early-stage clinical development that target novel pathways including the T cell immunoglobulin and mucin containing protein 3 (TIM-3) and lymphocyte-activation gene 3 (LAG-3) protein inhibitors, CD-47/signal regulatory protein a (SIRPa) and immunometabolic enzymes Indoleamine 2,3 dioxygenase-1 (IDO-1) which utilize an array of innovative delivery technologies such as small molecule agents, monoclonal antibodies, bispecific antibodies and fusion proteins to target inhibit checkpoint proteins.
Novel classes if checkpoint inhibitors will enter the market, companies will identify clinically effective combinations and validate biomarkers and signatures that will enable them to help identify patients that are most likely to benefit from treatment. Personalized precision medicine will be a major driver for pharma to effectively deliver these innovative medicines and ensure they are accessible and available at sustainable prices to all those in need.
The Report Includes:
- An overview of the global market for checkpoint inhibitors
- Analyses of global market trends, with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Discussion of the market landscape and innovative strategies, and the areas of unmet medical needs
- Information on the biomarker development, immune modulation, innovative delivery technologies, and the future landscape
- Market analysis for CP inhibitors, including PD-1/PD-L1 agents, CTLA-4 agents, TIM-3 agents, LAG-3 agents, IDO-1 agents, and SIRPa agents
- Comprehensive company profiles of major players in the industry, including Agenus, Inc., BeiGene, BIOCAD, Forty Seven, Inc., Seattle Genetics, Inc., Shanghai Cell Therapy, Tesaro, Inc. and Xencor
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Immuno-Oncology Market and Checkpoint Market Statistics
- Immuno-Oncology
- Co-Stimulatory Immune Checkpoint Targets
- Inhibitory Immune Checkpoint Targets
- Immunometabolic Modulatory Targets
- Unmet Medical Needs
- New Biomarkers to Stratify Patients
- Relapse/Refractory Patients
- Treatment Efficacy and Tolerability
- Innovative Strategies
- Emerging New Checkpoint Inhibitors
- New Combinations
- Novel Targeted Approaches
- Humanized Monoclonal Antibodies
- Bispecific Agents
- CAR-T Cells
- Current Market Landscape
- Marketed Checkpoint Inhibitors
- Developmental Checkpoint Inhibitors
Chapter 4 PD-1/PD-L1 Agents
- Introduction
- Marketed
- Pembrolizumab (Keytruda), Merck & Co.
- Companion Diagnostic
- Clinical Trial Program
- Pembrolizumab Forecasts
- Nivolumab (Opdivo), BMS
- Companion Diagnostic
- Clinical Trial Program
- Nivolumab Forecasts
- Atezolizumab (Tecentriq), Genentech
- Companion Diagnostic
- Clinical Trial Program
- Atezolizumab Forecasts
- Avelumab (Bavencio), Merck KGaA/Pfizer
- Companion Diagnostic
- Clinical Trial Program
- Avelumab Forecasts
- Durvalumab (Imfinzi), AstraZeneca
- Companion Diagnostic
- Clinical Trial Program
- Durvalumab Forecasts
- Cemiplimab (Libtayo), Regeneron/Sanofi
- Clinical Programs Phase 3
- Spartalizumab, Novartis
- Tislelizumab, BeiGene
- Clinical Programs Phase 2
- INCMGA0012, Incyte/MacroGenics
- LY3300054, Eli Lilly
- Clinical Programs Phase 1
- BI 754091, Boehringer Ingelheim
- CA-170, Curis/Aurigene
- CS1001, CStone Pharmaceuticals
- FS118, Merck KGaA/F-Star
- Preclinical Programs
- aCD27xaPD-L1, Celldex
- MEDI1109, AstraZeneca
- XmAb20717 and XmAb23104, Xencor
- Market Forecasts
Chapter 5 CTLA-4
- Introduction
- Marketed Drugs
- Yervoy (ipilimumab), BMS
- Clinical Programs Phase 3
- Tremelimumab, Astra Zeneca
- Clinical Programs Phase 1/2
- Anti-CTLA-4/PD-1 Expressing MUC1-CAR-T, Shanghai Cell Therapy
- Clinical Programs Phase 1
- AGEN-1884, Agenus
- BCD-145, Biocad
- CS1002, CStone Pharmaceuticals
- REGN4659, Regeneron Pharmaceuticals
- Market Forecasts
Chapter 6 IDO-1
- Introduction
- IDO-1 Developmental Therapies
- Clinical Programs Phase 3
- Epacadostat, Incyte
- Clinical Programs Phase 1
- BMS 986205, Bristol-Myers Squibb
- EOS200271, iTeos Therapeutics
- Indoximod (NLG-001) and Navoximod (NLG 919, GDC-0919, R6078), NewLink Genetics
- KHK2455, Kyowa Kirin
- LY3381916, Eli Lilly
- Preclinical Programs
- Market Forecasts
Chapter 7 LAG-3
- Introduction
- LAG-3 Developmental Therapies
- Clinical Programs Phase 2/3
- Relatlimab (BMS-986016), BMS
- Clinical Programs Phase 2
- LAG525 (IMP701), Novartis/Immuntep (Prima BioMed)
- Eftilagimod Alpha (IMP321), Immuntep (Prima BioMed)
- BI 754111, Boehringer Ingelheim
- FS118, Merck KGgaA/ F-star
- Sym022, Shire/Symphogen A/S
- TSR-033, Tesaro/Anaptys Bio
- XmAb22841, Xencor
- Preclinical Programs
- INCAGN02385, Incyte/Agenus
- Market Forecasts
Chapter 8 TIM-1,3
- Introduction
- TIM-1,3 Developmental Therapies
- Clinical Programs Phase 2
- Bavituximab, Merck Sharp & Dohme/Oncologie International
- Clinical Programs Phase 1/2
- CDX-014, Celldex Therapeutics/Seattle Genetics
- MGB453 +/- Spartalizumab, Novartis
- Clinical Programs Phase 1
- LY3321367 +/- LY3300054, Eli Lilly
- TSR-022 +/- TSR-042, Tesaro/AnaptysBio
- Preclinical Programs
- CA-327 (AUPM-327), Curis/Aurigene
- ENUM005, Enumeral Biomedical
- JNJ-64158120, Johnson & Johnson
- LY3321367, Eli Lilly
- STI-600, Sorrento Therapeutics
- Sym016, Symphogen A/S
- Market Forecasts
Chapter 9 CD47/SIRPa
- Introduction
- CD47-SIRPa Developmental Therapies
- Clinical Phase 1/2
- 5F9, Forty Seven Inc
- Clinical Programs Phase 1
- ALX148, ALX Oncology
- CC-90002, Celgene/InhibRx
- SRF231, Surface Oncology
- TTI-621, Trillium
- TTI-622, Trillium
- Preclinical Programs
- OSE-172, Boeringher Ingelheim/ OSE Immunotherapeutics
- INCAGN2390, Incyte/Agenus
- Market Forecasts
Chapter 10 Company Profiles
- ALX Oncology
- Agenus Inc.
- Anaptys Bio
- Beigene
- Biocad
- Cstone Pharmaceuticals
- Crescendo Biologics Ltd.
- F-Star Biotechnology
- Forty Seven, Inc.
- Immutep, Ltd.
- Inhibrx
- Macrogenics, Inc.
- OSE Immunotherapeutic
- Regeneron Pharmaceuticals, Inc.
- Seattle Genetics, Inc.
- Sorrento Therapeutics, Inc.
- Shanghai Cell Therapy
- Symphogen A/S
- Surface Oncology
- Tesaro, Inc.
- Trillium Therapeutics
- Xencor
Chapter 11 Appendix A: List of Abbreviations
Chapter 12 Appendix B: Glossary of Terms
Chapter 13 Appendix C: Sources
For more information about this report visit https://www.researchandmarkets.com/research/b94pdh/global_checkpoint?w=12
Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.